Amy Sheaffer
About Amy Sheaffer
Amy Sheaffer is the Translational Medicine Planning and Execution Lead at Bristol-Myers Squibb, with extensive experience in drug discovery and development in Immuno-Oncology and Virology.
Company
Amy Sheaffer currently works at Bristol-Myers Squibb, a global biopharmaceutical company, where she holds the position of Translational Medicine Planning and Execution Lead in Lawrenceville, NJ.
Title
Amy Sheaffer is currently the Translational Medicine Planning and Execution Lead at Bristol-Myers Squibb. In this role, she focuses on understanding the spectrum of patient responses to potential new treatments in Translational R&D.
Previous Roles at Bristol-Myers Squibb
Amy Sheaffer has held multiple roles at Bristol-Myers Squibb over the years. She was a Senior Research Investigator from 2017 to 2019 in Hopewell, NJ and currently holds the same title in Princeton, NJ. Additionally, she spent a considerable amount of time with the company from 1991 to 2016 as a Senior Research Investigator in Wallingford, Connecticut, making significant contributions to drug discovery projects in Immuno-Oncology and Virology.
Education and Expertise
Amy Sheaffer achieved a Doctor of Philosophy (Ph.D.) in Biomedical Sciences from The University of Connecticut Health Center, where she studied from 1995 to 2000. Prior to that, she obtained a Bachelor of Science (B.S.) in Microbiology from Pennsylvania State University, from 1988 to 1990. Her academic background has equipped her with extensive skills in molecular and cellular biology, immunology, and biochemistry techniques.
Early Career and Prior Experience
Before her long tenure at Bristol-Myers Squibb, Amy Sheaffer worked at Fox Chase Cancer Center as a Scientific Technician from 1990 to 1991 in Philadelphia, Pennsylvania. This early-stage role involved foundational scientific research that set the stage for her subsequent extensive career in translational medicine and drug discovery.
Research and Development Contributions
Throughout her career, Amy Sheaffer has led drug discovery projects focusing on antiviral drug discovery targeting HIV, oncogenic human Papillomaviruses, and Hepatitis C virus. She has designed and implemented functional assays using primary immune cells to support Oncology and Immuno-Oncology programs. Additionally, she has developed novel assays, validated potential targets, and explored the cellular processes affected by compounds identified through complex phenotypic whole-cell screens.